A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction

Medical Hypotheses

Volumn 79, Issue 5, 2012, Pages 673-677

  Della Rocca, Domenico G ^a,b   Willenberg, Bradley J ^a,c   Ferreira, Leonardo F ^d   Wate, Prateek S ^c   Petersen, John W ^a   Handberg, Eileen M ^a   Zheng, Tong ^a   Steindler, Dennis A ^a   Terada, Naohiro ^a   Batich, Christopher D ^c   Byrne, Barry J ^a   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c University of Florida   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; CALCIUM ALGINATE; COLLAGEN TYPE 1; FIBRIN GLUE; GELLING AGENT; MACROGOL; MATRIX PROTEIN;

ANGIOGENESIS; ARTICLE; CAPGEL; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; ENVIRONMENTAL FACTOR; HEART INFARCTION; HUMAN; HYDROGEL; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MYOFIBROBLAST; NONHUMAN; SCAR FORMATION; STEM CELL; STEM CELL TRANSPLANTATION; WOUND HEALING;

ALGINATES; HUMANS; HYDROGELS; MICROSCOPY, ELECTRON, SCANNING; MYOCARDIAL INFARCTION; STEM CELL FACTOR; STEM CELL TRANSPLANTATION;

EID: 84867336634     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.08.006     Document Type: Article

References (39)

1. Aoyagi T., Fujii A.M., Flanagan M.F., et al. Transition from compensated hypertrophy to intrinsic myocardial dysfunction during development of left ventricular pressure-overload hypertrophy in conscious sheep. Systolic dysfunction precedes diastolic dysfunction. Circulation 1993, 88:2415-2425.
2. Hellermann J.P., Goraya T.Y., Jacobsen S.J., et al. Incidence of heart failure after myocardial infarction: is it changing over time?. Am J Epidemiol 2003, 157(12):1101-1107.
3. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistic-2011 update: a report from the American Heart Association. Circulation 2011, 123:E18-E209.
4. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
5. Greenberg B., Quinones M.A., Koilpillai C., et al. Effects of long-term therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995, 91:2573-2581.
6. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37:1022-1036.
7. Segers V.F.M., Lee R.T. Biomaterials to enhance stem cell function in the heart. Circ Res 2011, 109:910-922.
8. Willenberg B.J., Hamazaki T., Meng F.W., Terada N., Batich C. Self-assembled copper-capillary alginate gel scaffolds with oligochitosan support embryonic stem cell growth. J Biomed Mater Res A 2006, 79(2):440-450.
9. Willenberg B.J., Zheng T., Meng F.W., et al. Gelatinized copper-capillary alginate gel functions as an injectable tissue scaffolding system for stem cell transplants. J Biomater Sci Polym Ed 2011, 22(12):1621-1637.
10. Perin E.C., Willerson J.T., Pepine C.J., et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012, 307(16):1717-1726.
11. Hatzistergos K.E., Quevedo H., Oskouei B.N., et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010, 107(7):913-922.
12. Bolli R., Chugh A.R., D'Amario D., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378(9806):1847-1857.
13. Kørbling M., Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept?. N Engl J Med 2003, 349(6):570-582.
14. Midwood K.S., Williams L.V., Schwarzbauer J.E. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 2004, 36(6):1031-1037.
15. Beltrami A.P., Urbanek K., Kajstura J., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001, 344:1750-1757.
16. Oh H., Bradfute S.B., Gallardo T.D., et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003, 100:12313-12318.
17. Wang X., Takagawa J., Lam V.C., et al. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med 2011, 3:100ra90.
18. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
19. Michel J.B. Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 2003, 23(12):2146-2154.
20. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010, 48(3):504-511.
21. Doyle B., Kemp B.J., Chareonthaitawee P., et al. Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction. J Nucl Med 2007, 48:1708-1714.
22. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94(12):1543-1553.
23. Singelyn J.M., Sundaramurthy P., Johnson T.D., et al. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol 2012, 59(8):751-763.
24. Zhao Z.Q., Puskas J.D., Xu D., et al. Improvement in cardiac function with small intestine extracellular matrix is associated with recruitment of C-kit cells, myofibroblasts, and macrophages after myocardial infarction. J Am Coll Cardiol 2010, 55(12):1250-1261.
25. Ma P.X. Scaffolds for tissue fabrication. Mater Today 2004, 7:30-40.
26. Zhang Y., Thorn S., DaSilva J.N., et al. Collagen-based matrices improve the delivery of transplanted circulating progenitor cells: development and demonstration by ex vivo radionuclide cell labeling and in vivo tracking with positron-emission tomography. Circ Cardiovasc Imaging 2008, 1(3):197-204.
27. Landa N., Miller L., Feinberg M.S., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117:1388-1396.
28. Leor J., Tuvia S., Guetta V., et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol 2009, 54:1014-1023.
29. Leor J., Aboulafia-Etzion S., Dar A., et al. Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium?. Circulation 2000, 102(19 Suppl. 3):III56-III61.
30. Danoviz M.E., Nakamuta J.S., Marques F.L., et al. Rat adipose tissue-derived stem cells transplantation attenuates cardiac dysfunction post infarction and biopolymers enhance cell retention. PLoS One 2010, 5:e12077.
31. Liu J., Hu Q., Wang Z., et al. Autologous stem cell transplantation for myocardial repair. Am J Physiol Heart Circ Physiol 2004, 287:H501-H511.
32. Christman K.L., Fok H.H., Sievers R.E., Fang Q., Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004, 10(3-4):403-409.
33. Kipshidze N., Chekanov V., Chawla P., et al. Angiogenesis in a patient with ischemic limb induced by intramuscular injection of vascular endothelial growth factor and fibrin platform. Tex Heart Inst J 2000, 27:196-200.
34. Dobner S., Bezuidenhout D., Govender P., Zilla P., Davies N. A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. J Card Fail 2009, 15:629-636.
35. Davis M.E., Motion J.P., Narmoneva D.A., et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005, 111(4):442-450.
36. Ikaria Holdings, Inc. IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction (PRESERVATION I). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012-[cited 2012 Jan 22]. Available from: http://www.clinicaltrials.gov/ct2/show/.
37. LoneStar Heart, Inc. A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure (AUGMENT-HF). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011-[cited 2012 Jan 22]. Available from: http://www.clinicaltrials.gov/ct2/show/.
38. LoneStar Heart, Inc. Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients with DCM Undergoing Open-Heart Surgery. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011-[cited 2012 Jan 22]. Available from: http://www.clinicaltrials.gov/ct2/show/.
39. Thumbs J., Kohler H.H. Capillaries in alginate gel as an example of dissipative structure formation. Chem Phys 1996, 208:9-24.